Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

Ruben Niesvizky, Scott Ely, Tomer Mark, Sangeeta Aggarwal, Janice L. Gabrilove, John J. Wright, Selina Chen-Kiang, Joseph A. Sparano

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Background: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. Methods: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m2) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). Results: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. Conclusions: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≤30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.

Original languageEnglish (US)
Pages (from-to)336-342
Number of pages7
JournalCancer
Volume117
Issue number2
DOIs
StatePublished - Jan 15 2011

Fingerprint

Histone Deacetylase Inhibitors
Multiple Myeloma
Histone Deacetylases
Therapeutics
Hypercalcemia
Tumor Suppressor Genes
Intravenous Infusions
Epigenomics
Histones
Chromatin
romidepsin
Proteins
Bone and Bones
Pain
Cell Line
DNA
Genes
Neoplasms

Keywords

  • histone deacetylase
  • inhibitor
  • myeloma
  • phase 2
  • recurrent/refractory
  • romidepsin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. / Niesvizky, Ruben; Ely, Scott; Mark, Tomer; Aggarwal, Sangeeta; Gabrilove, Janice L.; Wright, John J.; Chen-Kiang, Selina; Sparano, Joseph A.

In: Cancer, Vol. 117, No. 2, 15.01.2011, p. 336-342.

Research output: Contribution to journalArticle

Niesvizky, R, Ely, S, Mark, T, Aggarwal, S, Gabrilove, JL, Wright, JJ, Chen-Kiang, S & Sparano, JA 2011, 'Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma', Cancer, vol. 117, no. 2, pp. 336-342. https://doi.org/10.1002/cncr.25584
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan 15;117(2):336-342. https://doi.org/10.1002/cncr.25584
Niesvizky, Ruben ; Ely, Scott ; Mark, Tomer ; Aggarwal, Sangeeta ; Gabrilove, Janice L. ; Wright, John J. ; Chen-Kiang, Selina ; Sparano, Joseph A. / Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. In: Cancer. 2011 ; Vol. 117, No. 2. pp. 336-342.
@article{d3686a214c18451aac57b08d56393da0,
title = "Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma",
abstract = "Background: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. Methods: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m2) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). Results: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. Conclusions: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≤30{\%} in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.",
keywords = "histone deacetylase, inhibitor, myeloma, phase 2, recurrent/refractory, romidepsin",
author = "Ruben Niesvizky and Scott Ely and Tomer Mark and Sangeeta Aggarwal and Gabrilove, {Janice L.} and Wright, {John J.} and Selina Chen-Kiang and Sparano, {Joseph A.}",
year = "2011",
month = "1",
day = "15",
doi = "10.1002/cncr.25584",
language = "English (US)",
volume = "117",
pages = "336--342",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

AU - Niesvizky, Ruben

AU - Ely, Scott

AU - Mark, Tomer

AU - Aggarwal, Sangeeta

AU - Gabrilove, Janice L.

AU - Wright, John J.

AU - Chen-Kiang, Selina

AU - Sparano, Joseph A.

PY - 2011/1/15

Y1 - 2011/1/15

N2 - Background: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. Methods: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m2) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). Results: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. Conclusions: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≤30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.

AB - Background: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. Methods: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m2) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). Results: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. Conclusions: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≤30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.

KW - histone deacetylase

KW - inhibitor

KW - myeloma

KW - phase 2

KW - recurrent/refractory

KW - romidepsin

UR - http://www.scopus.com/inward/record.url?scp=78650992102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650992102&partnerID=8YFLogxK

U2 - 10.1002/cncr.25584

DO - 10.1002/cncr.25584

M3 - Article

C2 - 20862746

AN - SCOPUS:78650992102

VL - 117

SP - 336

EP - 342

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -